MBT-early: a Single Case Experimental Design
Launched by DE VIERSPRONG · Jan 9, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called MBT-early, is studying a new treatment approach for adolescents aged 12 to 18 who show early signs of borderline personality disorder (BPD). BPD can make it hard for young people to manage their emotions, maintain a stable sense of self, and interact with others. The researchers believe that if they can intervene early, they might help prevent more serious issues later on. The trial will focus on a specific therapy called MBT-early, which aims to improve personality functioning and reduce symptoms like depression by helping participants better understand their own thoughts and feelings and learn to trust others.
To be eligible for the study, young people need to have between three to six symptoms of BPD and experience mild to moderate difficulties in their daily lives, such as at school or home. However, those with certain other mental health diagnoses or severe functioning issues will not be included. Participants can expect to receive personalized therapy that targets their specific challenges, and the researchers will also look into how well the therapy works and what factors might help make it more effective. This study is currently recruiting participants, and it represents an important step in finding better ways to support young people with early signs of BPD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age between 12 and 18 years,
- • 2. Three to six traits of borderline personality disorder as assessed by the Structured Clinical Interview for DSM-5 Syndrome Disorders
- • 3. Mild to moderate disability with regard to functioning in school, at home and in the peer group.
- Exclusion Criteria:
- • 1. presence of a primary diagnosis that requires other specialist treatment (e.g. autism spectrum disorder, chronic psychotic disorder, severe eating disorder of sever substance abuse disorder),
- • 2. More than one comorbid classification,
- • 3. IQ \< 75,
- • 4. Severe disability with regard to functioning in school, at home and in the peer group representative for later stage BPD.
About De Viersprong
De Viersprong is a distinguished clinical trial sponsor dedicated to advancing mental health research and innovative treatment solutions. With a strong focus on evidence-based practices, the organization collaborates with leading researchers and healthcare professionals to design and conduct clinical trials that aim to improve therapeutic outcomes for individuals facing mental health challenges. Committed to ethical standards and patient safety, De Viersprong actively engages with participants and stakeholders to foster a collaborative environment that promotes scientific discovery and enhances the quality of care in the mental health field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halsteren, , Netherlands
Patients applied
Trial Officials
Maaike L. Smits, PhD
Principal Investigator
Psychotherapeutisch centrum de Viersprong, te Halsteren
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported